HSP90AA1 and cancer: Recent work has shown that dual-function inhibitors, such as MPT0G449, which simultaneously target histone deacetylases (HDACs) and Hsp90, cause disruption of key cancer-driving pathways with potent antitumor activity in models such as acute leukemia (23).